ESB 6228
SignedSenate
Prescription drugs/taxes
Removing a tax exemption for the warehousing and reselling of prescription drugs. (REVISED FOR ENGROSSED: Removing a tax exemption for the warehousing and reselling of prescription drugs and providing tax relief for critical access pharmacies.)
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill ends a long-standing tax exemption for businesses that warehouse and resell prescription drugs, instead applying a 0.5% business and occupation (B&O) tax to those activities. The change is intended to generate new state revenue to support essential services.
- Removes the existing tax exemption for warehousing and reselling prescription drugs for human use.
- Adds a new 0.5% business and occupation (B&O) tax on gross income from warehousing and reselling prescription drugs, effective January 1, 2027.
- Reenacts and amends RCW 82.04.280 to include prescription drug warehousing and reselling as a taxable activity.
- Repeals the prior law (RCW 82.04.272) that exempted this activity from taxation.
Who is affected
- Pharmaceutical wholesalers and retailers — Wholesalers and retailers of prescription drugs who currently benefit from a tax exemption on warehousing and reselling activities will now owe a 0.5% tax on gross income from those activities.
- Health care providers — Hospitals, clinics, and health care providers who purchase prescription drugs from taxable wholesalers may face slightly higher drug costs passed along from suppliers.
- State and local governments — The state will gain new tax revenue to support general fund services, and local governments may see modest increases in business and occupation (B&O) tax revenue.
Pro/Con Analysis
Potential Benefits (2)
The $25M in new annual revenue will support general fund services—including public safety, emergency response, and behavioral health programs—that benefit all Washingtonians, especially vulnerable populations who rely most heavily on publicly funded safety-net services.
Public SafetyPeopleRef: Sec. 1 (findings); Fiscal Impact ($25M annual revenue to general fund)Eliminating a targeted tax preference for a narrow sector (pharma wholesalers/retailers) improves tax equity by ensuring similar economic activities (e.g., warehousing of non-prescription goods) are taxed consistently—reducing distortions that currently favor high-margin drug distribution over other essential logistics sectors.
FinancialPeopleRef: Sec. 1 (findings); Sec. 2(g) (tax on warehousing/reselling of prescription drugs)
Potential Concerns (3)
Pharmaceutical wholesalers and retailers may pass increased tax costs to downstream providers (hospitals, clinics) and ultimately to patients through higher drug prices, potentially reducing access to medications—especially for low-income and chronically ill patients who are cost-sensitive.
HealthcarePeopleRef: Sec. 2(g); Sec. 2(f)(c) (new definition of 'warehousing and reselling drugs for human use pursuant to a prescription')Small-to-midsize pharmaceutical distributors and specialty pharmacies—especially those operating on thin margins—may face reduced profitability or be forced to consolidate, potentially leading to job losses or reduced service in rural or underserved areas where such firms are often the only local suppliers.
Business & EmploymentPeopleRef: Sec. 2(g); Sec. 3 (repeal of RCW 82.04.272); Fiscal Impact ($25M annual revenue)The tax applies to gross income, not net profit, meaning businesses operating at breakeven or with high overhead (e.g., compliance, cold-chain logistics) could be financially strained—even if ultimately profitable—potentially discouraging new market entrants or innovation in specialty drug distribution.
Business & EmploymentLean peopleRef: Sec. 2(g); Sec. 2(f)(c) (definition excludes only certain warehouses; includes 'reselling' of prescription drugs)
Who Is Most Affected
Pharmaceutical wholesalers and retailers—especially midsize and independent firms—will face new tax liability on gross income, squeezing margins in a low-margin industry. While large national distributors can absorb the cost more easily, smaller players may reduce staff or scale back operations, especially in rural communities.
Hospitals, clinics, and community health centers—particularly those serving Medicaid, uninsured, or underinsured patients—may face modestly higher drug acquisition costs if wholesalers pass along the tax. This could strain already tight budgets and potentially limit access to certain medications in safety-net settings.
State and local governments benefit directly from the $25M annual general fund revenue, which supports public safety, behavioral health, and emergency services. Local governments may also collect a portion of the B&O tax, though the bill does not specify allocation to localities—so the benefit is primarily state-level.
Low-income and elderly Washingtonians who rely on prescription medications may face indirect cost increases if drug distributors raise prices to cover the tax. However, the broader public services funded by the new revenue (e.g., SNAP, behavioral health, emergency response) disproportionately benefit these groups.
Pharmacy benefit managers (PBMs) and health insurers are not directly taxed, but may adjust reimbursement rates or formulary decisions in response to upstream cost increases. Their role as intermediaries means they may absorb or pass along costs, affecting premiums and out-of-pocket costs for consumers.